Long-term magnesium supplementation improves glucocorticoid metabolism 99 5 Results Study population A total of 51 participants completed the initial intervention trial. For the current posthoc analysis, data on 24-h urinary excretions of cortisol, cortisone and their metabolites were available from 49 participants. Baseline characteristics of the 49 participants that were included in the analysis are presented in Table 2. Their mean age was 62 ± 6 years and 22 (44.9%) were female. They had an average BMI of 29 ± 3 kg/ m2. Baseline measurements were comparable between the magnesium and placebo group (Table 2). Oral magnesium supplementation led to an increase in 24-h urinary magnesium excretion, (2.22 mmol/24-h; 95% CI: 1.38; 3.07 mmol/24-h, P<0.001) and a small, but non-significant, increase in plasma magnesium (0.01 mmol/L; 95% CI: -0.01; 0.04 mmol/L, P=0.170) (Table 3). Overall compliance was excellent, as evident by the increased 24-h urinary magnesium excretion observed in the magnesium group as well as the capsule counts. Compliance, based on the returned capsules, ranged from 86-102% and was on average 99% and 98% for the magnesium group and for the placebo group, respectively. The magnesium supplements were well tolerated. No serious adverse events were observed. Only mild headache and mild gastrointestinal complaints were reported for 7 days by 1 women from the magnesium group (during week 11 of the study). Table 2. Baseline characteristics of the included participants Variable Magnesium group (n = 25)a Placebo group (n = 24)a Females, % 48.0 41.7 Age, years 62.6 ± 5.3 61.5 ± 6.1 Body mass index, kg/m2 29.0 ± 2.5 29.8 ± 3.1 Waist circumference, cm 100 ± 9 103 ± 11 Serum triglycerides, mmol/L 1.33 ± 0.65 1.37 ± 0.52 Plasma glucose, mmol/L 5.52 ± 0.53 5.48 ± 0.61 Serum creatinine, µmol/L 79.8 ± 11.5 81.9 ± 13.5 Systolic blood pressure, mm Hg 134 ± 14 134 ± 18 Diastolic blood pressure, mm Hg 87 ± 8 90 ± 11 Heart rate, beats/min 66 ± 8 68 ± 6 aValues are means ± SDs or percentages.
RkJQdWJsaXNoZXIy MTk4NDMw